Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital

Heterogeneity of treatment effect of prophylactic pantoprazole in adult ICU patients: a post hoc analysis of the SUP-ICU trial

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Tracheostomy practice and timing in traumatic brain-injured patients: a CENTER-TBI study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Noninvasive respiratory support in the hypoxaemic peri-operative/periprocedural patient: a joint ESA/ESICM guideline

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Lactate versus acetate buffered intravenous crystalloid solutions: a scoping review

    Research output: Contribution to journalReviewResearchpeer-review

  2. Evaluating Non-Statistically Significant Results From Trials in Practice-Reply

    Research output: Contribution to journalComment/debateResearchpeer-review

View graph of relations

PURPOSE: The Stress Ulcer Prophylaxis in the Intensive Care Unit (SUP-ICU) trial compared prophylactic pantoprazole with placebo in 3291 adult ICU patients at risk of clinically important gastrointestinal bleeding (CIB). As a predefined subgroup analysis suggested increased 90-day mortality with pantoprazole in the most severely ill patients, we aimed to further explore whether heterogenous treatment effects (HTE) were present.

METHODS: We assessed HTE in subgroups defined according to illness severity by SAPS II quintiles and the total number of risk factors for CIB using Bayesian hierarchical models, and on the continuous scale using Bayesian logistic regression models with interactions. Estimates were presented as posterior probability distributions of odds ratios (ORs), probabilities of different effect sizes, and marginal effects plots.

RESULTS: We observed potential HTE for 90-day mortality according to illness severity (median subgroup OR range 0.90-1.09) with higher risk in the most severely ill, but not with different numbers of risk factors (1.00-1.02). We observed potential HTE of pantoprazole for clinically important events (0.86-1.18) and infectious adverse events (0.88-1.27) with higher risk in patients with greater illness severity and in those with more risk factors for CIB. Pantoprazole substantially and consistently reduced the risk of CIB with no indications of HTE (0.53-0.63).

CONCLUSIONS: In this post hoc analysis of the SUP-ICU trial, we found indications of HTE with increased risks of serious adverse events in patients with greater illness severity or more risk factors for CIB allocated to pantoprazole. These findings are hypothesis-generating and warrant further prospective investigation. CLINICALTRIALS.


Original languageEnglish
JournalIntensive Care Medicine
Issue number4
Pages (from-to)717-726
Number of pages10
Publication statusPublished - Apr 2020

    Research areas

  • Bayesian analysis, Gastrointestinal bleeding, Heterogeneity of treatment effects, Pantoprazole, Stress ulcer prophylaxis, Subgroup analysis

ID: 59134835